| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1036534533 |
| P356 | DOI | 10.1186/2047-783X-16-4-153 |
| P932 | PMC publication ID | 3352071 |
| P698 | PubMed publication ID | 21486729 |
| P50 | author | Cornelia Lass-Florl | Q87722456 |
| Astrid Mayr | Q90404418 | ||
| P2860 | cites work | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 |
| Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 | ||
| Invasive aspergillosis in the intensive care unit | Q28306909 | ||
| In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B | Q28343867 | ||
| Epidemiology of invasive candidiasis: a persistent public health problem | Q29616758 | ||
| Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism | Q30853962 | ||
| Acquired itraconazole resistance in Aspergillus fumigatus | Q32061952 | ||
| Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. | Q51184875 | ||
| Multi-azole resistance in Aspergillus fumigatus | Q56837308 | ||
| Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection | Q56837366 | ||
| Multiple-Triazole–Resistant Aspergillosis | Q63914862 | ||
| In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. acquired resistance to itraconazole | Q74064109 | ||
| The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study | Q80050239 | ||
| Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey | Q80052810 | ||
| Invasive aspergillosis in critically ill patients without malignancy | Q80269940 | ||
| Hospital-wide prospective mandatory surveillance of invasive aspergillosis in a French teaching hospital (2000-2002) | Q81417212 | ||
| Targeted gene disruption of the 14-alpha sterol demethylase (cyp51A) in Aspergillus fumigatus and its role in azole drug susceptibility. | Q33836567 | ||
| Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. | Q34042225 | ||
| DifferentialAspergillus lentulusEchinocandin Susceptibilities Are Fksp Independent | Q34309395 | ||
| Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience | Q34455699 | ||
| Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients | Q34553509 | ||
| Management of mycoses in surgical patients -- review of the literature. | Q34691691 | ||
| New methods to assess susceptibilities of Aspergillus isolates to caspofungin | Q34956645 | ||
| Caspofungin: the first in a new class of antifungal agents | Q35214623 | ||
| Prevention of fungal infections in the immunocompromised host | Q35543286 | ||
| In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection | Q35870651 | ||
| Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. | Q35912243 | ||
| Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin | Q36235197 | ||
| Update on antifungal drug resistance mechanisms of Aspergillus fumigatus | Q36401128 | ||
| Resistance to echinocandin-class antifungal drugs | Q36849595 | ||
| Multidrug resistance in fungi | Q36943181 | ||
| Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact | Q37048679 | ||
| Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. | Q37115801 | ||
| Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals | Q37120030 | ||
| The changing face of epidemiology of invasive fungal disease in Europe | Q37458702 | ||
| Azole-resistance in Aspergillus: proposed nomenclature and breakpoints | Q37625111 | ||
| The echinocandins: three useful choices or three too many? | Q37639737 | ||
| Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. | Q37783285 | ||
| Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. | Q39687164 | ||
| Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus | Q39784524 | ||
| Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin | Q40433967 | ||
| Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles | Q41370116 | ||
| Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain | Q41846354 | ||
| A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. | Q42048818 | ||
| In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species | Q42078338 | ||
| Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins. | Q42104497 | ||
| Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era. | Q42446554 | ||
| Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure | Q42555868 | ||
| Potential risk factors for infection with Candida spp. in critically ill patients. | Q43931137 | ||
| Risk factors for candidaemia in critically ill patients: a prospective surveillance study | Q44217079 | ||
| Multidrug resistance in Aspergillus fumigatus. | Q44261807 | ||
| Disseminated aspergillosis in intensive care unit patients: an autopsy study | Q44392075 | ||
| Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases | Q45015455 | ||
| Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma | Q45162537 | ||
| Azole-resistant central nervous system aspergillosis. | Q46094844 | ||
| Disruption of the Aspergillus fumigatus ECM33 homologue results in rapid conidial germination, antifungal resistance and hypervirulence | Q46769804 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | epidemiology | Q133805 |
| antifungal | Q578726 | ||
| antifungal drug resistance | Q53788821 | ||
| invasive pulmonary aspergillosis | Q54946623 | ||
| 14-alpha sterol demethylase | Q61546270 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 153-157 | |
| P577 | publication date | 2011-04-01 | |
| 2011-04-28 | |||
| P1433 | published in | European Journal of Medical Research | Q5412732 |
| P1476 | title | Epidemiology and antifungal resistance in invasive Aspergillosis according to primary disease: review of the literature | |
| P478 | volume | 16 |
| Q52673294 | Acylhydrazones as Antifungal Agents Targeting the Synthesis of Fungal Sphingolipids. |
| Q47149131 | An invisible threat: mutation-mediated resistance to triazole drugs in Aspergillus |
| Q92219338 | Antifungal Resistance in Clinical Isolates of Aspergillus spp.: When Local Epidemiology Breaks the Norm |
| Q39796605 | Antifungal susceptibility of 175 Aspergillus isolates from various clinical and environmental sources |
| Q51032695 | Aspergillus fumigatus devoid of cell wall β-1,3-glucan is viable, massively sheds galactomannan and is killed by septum formation inhibitors. |
| Q34298083 | Cryptic and rare Aspergillus species in Brazil: prevalence in clinical samples and in vitro susceptibility to triazoles |
| Q92637744 | Detecting Azole-Antifungal Resistance in Aspergillus fumigatus by Pyrosequencing |
| Q39091924 | Diagnosis, classification, and therapeutic interventions for sinopulmonary Aspergillosis |
| Q46893764 | Does fungicide application in vineyards induce resistance to medical azoles in Aspergillus species? |
| Q39458862 | Echinocandins in antifungal pharmacotherapy. |
| Q42573050 | Efficacy of Amphotericin B at Suboptimal Dose Combined with Voriconazole in a Murine Model of Aspergillus fumigatus Infection with Poor In Vivo Response to the Azole |
| Q50718095 | Evaluation of Etest performed in Mueller-Hinton agar supplemented with glucose for antifungal susceptibility testing of clinical isolates of filamentous fungi. |
| Q33421462 | Identification of Aspergillus fumigatus Surface Components That Mediate Interaction of Conidia and Hyphae With Human Platelets |
| Q36059265 | Identification of Ebsulfur Analogues with Broad-Spectrum Antifungal Activity |
| Q40936437 | In Vivo Synergy of Amphotericin B plus Posaconazole in Murine Aspergillosis |
| Q36276895 | In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model |
| Q40045666 | Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi |
| Q37617395 | Regulation of Sterol Biosynthesis in the Human Fungal Pathogen Aspergillus fumigatus: Opportunities for Therapeutic Development |
| Q35034529 | SNaPAfu: a novel single nucleotide polymorphism multiplex assay for aspergillus fumigatus direct detection, identification and genotyping in clinical specimens |
| Q38774244 | Special Issue: Novel Antifungal Drug Discovery |
| Q38937577 | The anti-Aspergillus drug pipeline: Is the glass half full or empty? |
| Q35196866 | The application of laser microdissection in molecular detection and identification of aspergillus fumigatus from murine model of acute invasive pulmonary aspergillosis |
| Q38334381 | The molecular mechanism of azole resistance in Aspergillus fumigatus: from bedside to bench and back. |
| Q37964703 | Triazole antifungal agents in invasive fungal infections: a comparative review |
| Q64904368 | Unravelling species boundaries in the Aspergillus viridinutans complex (section Fumigati): opportunistic human and animal pathogens capable of interspecific hybridization. |
Search more.